๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Mantle Cell Lymphoma (MCL)
Clinical trial register · China

Mantle Cell Lymphoma (MCL) Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Shanghai 4 Guangzhou 3 Beijing 2 Zhengzhou 2 Hangzhou 1
Narrow the registerReset
Recruitment status
Phase
Site location
Shanghai4 Guangzhou3 Beijing2 Zhengzhou2 Hangzhou1
All 14 locations
Target enrolment
to

Mantle Cell Lymphoma (MCL) trials in China

13 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Orelabrutinib Combined With Obinutuzumab and Short-Course Venetoclax in Patients With Treatment-Naรฏve Mantle Cell Lymphoma (MCL)
NCT07719556Mantle Cell Lymphoma (MCL)
The First Affiliated Hospital with Nanjing Medical University
Phase 2
39
Changzhou, Nanjing
2026-07-15
Recruiting
A Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell Malignancies
NCT07609862Mantle Cell Lymphoma (MCL), Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma ( FL), Waldenstrรถm Macroglobulinemia (WM)
Guangzhou Lupeng Pharmaceutical Company LTD.
Phase 1/2
92
Tianjin
2026-07-14
Not yet open
Lisaftoclax Plus Pirtobrutinib in Relapsed or Refractory Mantle Cell Lymphoma After BTK-Targeted Therapy
NCT07684950Mantle Cell Lymphoma (MCL)
Henan Cancer Hospital
Phase 2
45
Zhengzhou
2026-06-30
Not yet open
ZSDT for the Treatment of R/R Mantle Cell Lymphoma After BTK Inhibitor Failure: a Multi-center Prospective Clinical Trial
NCT07264894Mantle Cell Lymphoma (MCL)
Zhengzhou University
Phase 4
30
Zhengzhou
2025-12-31
Recruiting
Relmacabtagene Autoleucel Combined With Sintilimab for Relapsed/Refractory B-cell Lymphoma
NCT07077512Large B Cell Diffuse Lymphoma, Mantle Cell Lymphoma (MCL), Follicular Lymphoma ( FL)
Sun Yat-sen University
Phase 2
30
Guangzhou
2025-09-15
Recruiting
Orelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With High-Risk Disease
NCT07272499Mantle Cell Lymphoma (MCL)
Ruijin Hospital
Phase 2
25
Shanghai
2025-09-10
Recruiting
Pomalidomide Plus Orelabrutinib and Zuberitamab in Untreated Mantle Cell Lymphoma
NCT07257510Mantle Cell Lymphoma (MCL), POZ
Peking University Third Hospital
Not applicable
34
Beijing
2025-08-01
Recruiting
Orelabrutinib and Rituximab With Optional Autologous Hematopoietic Stem Cell Transplantation in MCL Treatment
NCT07199296Mantle Cell Lymphoma (MCL)
Ruijin Hospital
Phase 2
45
Shanghai
2025-07-01
Recruiting
Acalabrutinib Plus Rituximab for the Treatment of Elderly or Low- to Intermediate-Risk Younger Untreated Mantle Cell Lymphoma
NCT06846489Mantle Cell Lymphoma (MCL)
Sun Yat-sen University
Phase 2
50
Guangzhou
2025-04-14
Recruiting
Bendamustine and Rituximab With or Without Orelabrutinib in MCL Treatment
NCT06496308Mantle Cell Lymphoma (MCL)
Ruijin Hospital
Phase 3
78
Shanghai
2024-07-10
By invitation
Real-world Study of Acalabrutinib
NCT06767891Mantle Cell Lymphoma (MCL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Ruijin Hospital
Observational
160
Shanghai
2024-07-02
Recruiting
Sequential Treatment of CD19 CARNK and 7x19 CAR-T in R/R B Cell Lymphoma
NCT06464861Primary Mediastinal B-cell Lymphoma (PMBCL), Mantle Cell Lymphoma (MCL), Diffuse Large B Cell Lymphoma( DLBCL)
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 1
52
Hangzhou
2024-06-20
Active, closed
A Study of Rocbrutinib in Participants With Relapse or Refractory Mantle Cell Lymphoma
NCT05716087Mantle Cell Lymphoma (MCL)
Guangzhou Lupeng Pharmaceutical Company LTD.
Phase 2
62
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Guangzhou, Meizhou
2023-02-21
Rows per page Showing 1–13 of 13
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/condition/mantle-cell-lymphoma-mcl

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 13 of those studies listing the condition Mantle Cell Lymphoma (MCL).

How many Mantle Cell Lymphoma (MCL) trials are recruiting in China?

9 of the 13 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 2 have not yet opened recruitment, 1 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Mantle Cell Lymphoma (MCL)), 13 studies
PhaseStudiesRecruitingShare
Phase 27553.8%
Not applicable117.7%
Observational107.7%
Phase 1117.7%
Phase 1/2117.7%
Phase 3117.7%
Phase 4107.7%

Most active sponsors

Lead sponsors with the most studies (Mantle Cell Lymphoma (MCL))
Lead sponsorStudiesRecruiting
Ruijin Hospital43
Guangzhou Lupeng Pharmaceutical Company LTD.21
Sun Yat-sen University22
Henan Cancer Hospital10
Peking University Third Hospital11
Second Affiliated Hospital, Zhejiang University, School of Medicine11
The First Affiliated Hospital with Nanjing Medical University11
Zhengzhou University10
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.